Israeli company Brainsway Ltd., which develops non-invasive treatments using transcranial magnetic stimulation (TMS), has received the EU’s CE Marketing stamp of approval for its Deep TMS system. The company will use the system for treating autism, Alzheimer’s and cigarette addiction.
The approval was granted by MedCert, which is qualified for approving medical treatments by CE Marketing. Earlier this year, Brainsway won FDA and Health Canada approval.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments